Cadrenal Therapeutics, Inc. (CVKD) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cadrenal Therapeutics, Inc. on August 16, 2024. The Company is a Delaware corporation with its principal executive offices in Ponte Vedra, Florida. The report details a material corporate action regarding the Company's capital structure intended to maintain its listing on the Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed relates to the Company's share count:
- Pre-Split Outstanding Shares: Approximately 16 million shares.
- Post-Split Outstanding Shares: Approximately 1.1 million shares.
- Stock Symbol: CVKD (Nasdaq Capital Market).
Material Changes
The Company announced a 1-for-15 reverse stock split of its Common Stock. Key details include:
- Approval: Stockholders approved the split at the Annual Meeting on July 29, 2024, with the Board selecting the 1-for-15 ratio.
- Effective Date: The split will become effective at 12:01 a.m. Eastern Time on August 20, 2024.
- Trading: Trading on a split-adjusted basis will commence when the Nasdaq opens on August 20, 2024.
- Fractional Shares: No fractional shares will be issued. Shareholders entitled to fractional shares will receive a cash payment based on the average closing sales price of the Common Stock for the ten days preceding the Effective Time.
- Adjustments: Proportional adjustments will be made to outstanding equity awards and warrants, including exercise prices.
Outlook, Risks, and Management Commentary
Management states the primary objective of the reverse stock split is to bring the Company into compliance with the Nasdaq Capital Market's minimum bid price requirement, which mandates a minimum bid price of at least $1.00 per share. The Company also intends to make the bid price more attractive to investors. The filing notes that the description of the Certificate of Amendment is qualified by the full text of the document attached as Exhibit 3.1.
Investor Verification Checklist
- Verify the effective time of the reverse stock split (August 20, 2024, 12:01 a.m. ET) and the start of split-adjusted trading.
- Confirm the new CUSIP number for the Common Stock (127636 207).
- Review the calculation methodology for cash payments in lieu of fractional shares (average closing price over the ten days preceding the Effective Time).
- Check the status of outstanding equity awards and warrants to ensure exercise prices and share counts have been adjusted proportionally.
- Monitor the stock price post-split to ensure compliance with the $1.00 minimum bid price requirement.